Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, will host a conference call and webcast to report its first quarter 2019 financial results and provide a corporate update on Tuesday, May 7, 2019.
| SAN FRANCISCO, April 30, 2019 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, will host a conference call and webcast to report its first quarter 2019 financial results and provide a corporate update on Tuesday, May 7, 2019. The conference call will be held at 4:30 pm EDT. To access a live webcast of the conference call, please visit the Events & Presentations page within the Investor + Media section of the Audentes website at www.audentestx.com. Alternatively, please call (833) 659-8620 (U.S.) or (409) 767-9247 (international) and dial the conference ID# 6839198 to access the call. A replay of the live webcast will be available on the Audentes website for approximately 30 days. About Audentes Therapeutics, Inc. For more information regarding Audentes, please visit www.audentestx.com. Audentes Contacts: Investor Contact: Media Contacts: Katie Hogan
SOURCE Audentes Therapeutics, Inc. | ||
Company Codes: NASDAQ-NMS:BOLD |
View original content to download multimedia:
